Trial Profile
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ordesekimab (Primary)
- Indications Coeliac disease
- Focus Therapeutic Use
- Sponsors Amgen; Celimmune
- 05 Jun 2018 Results presented at the Digestive Disease Week 2018
- 30 Jan 2018 Status changed from active, no longer recruiting to completed.
- 01 Apr 2017 This trial was completed in Finland, according to European Clinical Trials Database.